2-[[(5R)-6-amino-5-hydroxyhexanoyl]amino]acetic acid | 1230070-66-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[[(5R)-6-amino-5-hydroxyhexanoyl]amino]acetic acid
• CAS: 1230070-66-2
• 化学式: C₈H₁₆N₂O₄
• 分子量: 204.226
• InChiKey: HFCJYYPRGKCQEF-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.1
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  tert-butyl (R)-5-(4-((2-(tert-butoxy)-2-oxoethyl)amino)-4-oxobutyl)-2,2-dimethyloxazolidine-3-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 1.0h， 以62%的产率得到2-[[(5R)-6-amino-5-hydroxyhexanoyl]amino]acetic acid
  参考文献：
  名称：

  Negamycin Analogue with Readthrough-Promoting Activity as a Potential Drug Candidate for Duchenne Muscular Dystrophy

  摘要：

  A series of (+)-negamycin 1 analogues were synthesized, and their readthrough-promoting activity was evaluated for nonsense mutations in Duchenne muscular dystrophy 3 (DMD). A structure activity relationship study indicated that 11b was the most potent drug 0 candidate. Immunohistochemical analyses suggested that treatment with 11b restored dystrophin expression in mdx mice, a DMD mouse model. Furthermore, lib decreased serum creatine kinase (CK) levels, an indicator of muscle fiber destruction. Most importantly, 11b demonstrated lower toxicity than 1, and thus, it could be a useful candidate for long-term treatment of DMD.

  DOI：

  10.1021/ml200245t

文献信息

• Methods for inducing an immune response
  申请人：MOONSHOT PHARMA LLC

  公开号：US11135221B2

  公开（公告）日：2021-10-05

  Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through and inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing PTCs.

  本文特别提供了通过促进过早终止密码子（PTC）读通和抑制带有 PTC 的信使核糖核酸（mRNA）的无意义介导衰变（NMD），在个体中产生免疫反应和/或诱导异常（如增殖）细胞表面表达新抗原的组合物和方法。
• METHODS FOR INDUCING AN IMMUNE RESPONSE BY PROMOTING PREMATURE TERMINATION CODON READ-THROUGH
  申请人：MOONSHOT PHARMA LLC

  公开号：US20190350908A1

  公开（公告）日：2019-11-21

  Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through of messenger RNAs (mRNAs) bearing PTCs.
• METHODS FOR TREATING CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE MODULATORS
  申请人：MOONSHOT PHARMA LLC

  公开号：US20200155519A1

  公开（公告）日：2020-05-21

  Disclosed herein are compositions and methods for treating cancer in a subject. In some embodiments, the methods involve generating an immune response in an individual by inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells. In one embodiment, a method of treating cancer in a subject includes administering amlexanox in combination with immune modulators, such as checkpoint inhibitors, immune co-stimulatory molecules, TLR agonists, and TNFR superfamily agonists. In one embodiment, the checkpoint inhibitors are selected from antibodies against PD-1, PD-L1, and CTLA-4.
• METHODS FOR INDUCING AN IMMUNE RESPONSE
  申请人：MOONSHOT PHARMA LLC

  公开号：US20220000865A1

  公开（公告）日：2022-01-06

  Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through and inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing PTCs.
• Negamycin Analogue with Readthrough-Promoting Activity as a Potential Drug Candidate for Duchenne Muscular Dystrophy
  作者：Akihiro Taguchi、Shigenobu Nishiguchi、Masataka Shiozuka、Takao Nomoto、Mayuko Ina、Shouta Nojima、Ryoichi Matsuda、Yoshiaki Nonomura、Yoshiaki Kiso、Yuri Yamazaki、Fumika Yakushiji、Yoshio Hayashi

  DOI：10.1021/ml200245t

  日期：2012.2.9

  A series of (+)-negamycin 1 analogues were synthesized, and their readthrough-promoting activity was evaluated for nonsense mutations in Duchenne muscular dystrophy 3 (DMD). A structure activity relationship study indicated that 11b was the most potent drug 0 candidate. Immunohistochemical analyses suggested that treatment with 11b restored dystrophin expression in mdx mice, a DMD mouse model. Furthermore, lib decreased serum creatine kinase (CK) levels, an indicator of muscle fiber destruction. Most importantly, 11b demonstrated lower toxicity than 1, and thus, it could be a useful candidate for long-term treatment of DMD.